MY171180A - Anti-hla-b*27 antibodies and uses thereof - Google Patents
Anti-hla-b*27 antibodies and uses thereofInfo
- Publication number
- MY171180A MY171180A MYPI2014002668A MYPI2014002668A MY171180A MY 171180 A MY171180 A MY 171180A MY PI2014002668 A MYPI2014002668 A MY PI2014002668A MY PI2014002668 A MYPI2014002668 A MY PI2014002668A MY 171180 A MY171180 A MY 171180A
- Authority
- MY
- Malaysia
- Prior art keywords
- hla
- antibodies
- present
- binding
- certain embodiments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261618969P | 2012-04-02 | 2012-04-02 | |
US201361778703P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY171180A true MY171180A (en) | 2019-09-30 |
Family
ID=48093122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2014002668A MY171180A (en) | 2012-04-02 | 2013-04-02 | Anti-hla-b*27 antibodies and uses thereof |
Country Status (22)
Country | Link |
---|---|
US (1) | US9790273B2 (fr) |
EP (1) | EP2834272B1 (fr) |
JP (1) | JP6320993B2 (fr) |
KR (1) | KR20150003256A (fr) |
CN (1) | CN104169302A (fr) |
AR (1) | AR090585A1 (fr) |
AU (1) | AU2013243644C1 (fr) |
BR (1) | BR112014024622A2 (fr) |
CA (1) | CA2868907C (fr) |
CL (1) | CL2014002631A1 (fr) |
CO (1) | CO7121320A2 (fr) |
EA (1) | EA201491827A1 (fr) |
HK (1) | HK1207092A1 (fr) |
IL (2) | IL234707A0 (fr) |
MX (1) | MX365690B (fr) |
MY (1) | MY171180A (fr) |
NZ (1) | NZ700650A (fr) |
PH (1) | PH12014502184A1 (fr) |
SG (2) | SG10201608136SA (fr) |
TW (1) | TWI619729B (fr) |
UY (1) | UY34721A (fr) |
WO (1) | WO2013152001A2 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
EP3689912A1 (fr) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
US20140093496A1 (en) | 2011-02-25 | 2014-04-03 | Chugai Seiyaku Kabushiki Kaisha | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY |
US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
US20150056182A1 (en) | 2011-11-30 | 2015-02-26 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗-hla-b*27抗體及其用途 |
EP2877580B1 (fr) | 2012-07-27 | 2019-01-30 | City of Hope | Vaccin mva pour l'administration d'un complexe ul128 et la prévention d'une infection par cmv |
EP3597747B1 (fr) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps fc spécifiques fcgammarii de souris |
MX371442B (es) | 2012-08-24 | 2020-01-30 | Chugai Pharmaceutical Co Ltd | VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB. |
WO2014104165A1 (fr) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | Polypeptide hétérodimérisé |
EP3783017A1 (fr) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Variant de région fc |
CA2963760A1 (fr) | 2014-12-19 | 2016-06-23 | Yoshinao Ruike | Anticorps anti-myostatine, polypeptides contenant des variants de regions fc, et procedes d'utilisation |
CN113045650A (zh) | 2014-12-19 | 2021-06-29 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
CA2973641A1 (fr) * | 2015-02-04 | 2016-08-11 | Universitat Zurich | Utilisation d'homodimeres de hla-b27 pour le traitement du cancer |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
ES2923895T3 (es) * | 2015-02-27 | 2022-10-03 | Icell Gene Therapeutics Llc | Receptores de antígeno quimérico (CARS) dirigidos a neoplasisas malignas hematológicas, composiciones y métodos de uso de los mismos |
US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
CA2990177A1 (fr) | 2015-06-25 | 2016-12-29 | Icell Gene Therapeutics Llc | Recepteurs d'antigenes chimeriques, compositions et methodes associees |
EP3341738A4 (fr) | 2015-08-24 | 2019-02-27 | University of Cincinnati | Procédés et compositions permettant la détection de l'activité de liaison au récepteur fc d'anticorps |
WO2017044895A2 (fr) * | 2015-09-10 | 2017-03-16 | City Of Hope | Anticorps générés par le vaccin mva-gh/gl-pc neutralisant le pouvoir infectieux du cytomégalovirus humain et procédés associés |
CR20180364A (es) * | 2015-12-18 | 2018-08-22 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos de uso |
KR20240058997A (ko) * | 2015-12-18 | 2024-05-03 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
EP3394098A4 (fr) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-myostatine et procédés d'utilisation |
CA3029197A1 (fr) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Recepteurs d'antigenes chimeriques (car), compositions et procedes associes |
CA3026050A1 (fr) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition pour la prophylaxie ou le traitement de maladies liees a il-8 |
AU2017309314A1 (en) | 2016-08-10 | 2019-02-07 | Universität Basel | MHC class Ia open conformers |
JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
CN110520145A (zh) * | 2017-03-31 | 2019-11-29 | 阿尔玛生物医疗公司 | Hla-b27相关炎性疾病的治疗方法及相关组合物 |
CN108486226B (zh) * | 2018-04-01 | 2022-04-12 | 广东辉锦创兴生物医学科技有限公司 | Hla-b27等位基因的检测试剂盒及其应用 |
CN113853204A (zh) * | 2019-03-21 | 2021-12-28 | 盖米达细胞有限公司 | 适用于移植组合疗法的扩增nk细胞组分的扩增及其用途 |
CN111175490A (zh) * | 2020-01-19 | 2020-05-19 | 泛肽生物科技(浙江)有限公司 | 一种定性检测hla-b27的试剂盒及其检测方法 |
IL306046A (en) * | 2021-04-07 | 2023-11-01 | Regeneron Pharma | A preparation for use in the treatment of disorders related to MHC-1 |
WO2023220263A1 (fr) * | 2022-05-13 | 2023-11-16 | Memorial Sloan-Kettering Cancer Center | Compositions et procédés de modulation de tcr |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340610C (fr) * | 1985-08-16 | 1999-06-29 | Karen A. Nelson | Anticorps monoclonal pour antigene hla-b27 humain |
US5369010A (en) | 1985-08-16 | 1994-11-29 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant -B27 |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2005103081A2 (fr) | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
US20130315933A1 (en) | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗-hla-b*27抗體及其用途 |
-
2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/zh not_active IP Right Cessation
- 2013-04-02 CA CA2868907A patent/CA2868907C/fr active Active
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/pt not_active IP Right Cessation
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 US US13/855,448 patent/US9790273B2/en active Active
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/ko not_active Application Discontinuation
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/fr active Active
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/ja active Active
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/fr active Application Filing
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en active Active
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 UY UY0001034721A patent/UY34721A/es not_active Application Discontinuation
- 2013-04-02 MX MX2014011898A patent/MX365690B/es active IP Right Grant
- 2013-04-02 EA EA201491827A patent/EA201491827A1/ru unknown
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/zh active Pending
- 2013-04-03 AR ARP130101081A patent/AR090585A1/es unknown
-
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/es unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/es unknown
-
2015
- 2015-08-10 HK HK15107698.3A patent/HK1207092A1/xx unknown
-
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN104169302A (zh) | 2014-11-26 |
KR20150003256A (ko) | 2015-01-08 |
CA2868907C (fr) | 2022-01-04 |
US20130259876A1 (en) | 2013-10-03 |
UY34721A (es) | 2013-10-31 |
MX2014011898A (es) | 2014-11-12 |
MX365690B (es) | 2019-06-11 |
AU2013243644C1 (en) | 2018-05-10 |
NZ700650A (en) | 2017-02-24 |
SG10201608136SA (en) | 2016-11-29 |
PH12014502184A1 (en) | 2014-12-10 |
CO7121320A2 (es) | 2014-11-20 |
TW201343675A (zh) | 2013-11-01 |
JP2015514110A (ja) | 2015-05-18 |
IL234707A0 (en) | 2014-11-30 |
WO2013152001A2 (fr) | 2013-10-10 |
CA2868907A1 (fr) | 2013-10-10 |
EP2834272A2 (fr) | 2015-02-11 |
CL2014002631A1 (es) | 2015-01-16 |
SG11201405759UA (en) | 2014-11-27 |
EP2834272B1 (fr) | 2020-06-24 |
JP6320993B2 (ja) | 2018-05-09 |
IL256716A (en) | 2018-03-29 |
EA201491827A1 (ru) | 2015-03-31 |
AU2013243644A1 (en) | 2014-10-23 |
AR090585A1 (es) | 2014-11-26 |
US9790273B2 (en) | 2017-10-17 |
TWI619729B (zh) | 2018-04-01 |
BR112014024622A2 (pt) | 2017-08-08 |
HK1207092A1 (en) | 2016-01-22 |
AU2013243644B2 (en) | 2018-02-08 |
WO2013152001A3 (fr) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY171180A (en) | Anti-hla-b*27 antibodies and uses thereof | |
WO2017015622A8 (fr) | Protéines de liaison à gdf11 et leurs utilisations | |
SG10201907215QA (en) | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof | |
WO2013048883A3 (fr) | Anticorps anti-erbb3 et leurs utilisations | |
WO2014089169A3 (fr) | Immunothérapie par des agents de liaison | |
EA201492101A1 (ru) | Антитела против fcrn | |
MA40609B1 (fr) | Agents de liaison cd123 et leurs utilisations | |
MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
TN2012000366A1 (en) | Anticoagulant antidotes | |
MY195289A (en) | Anti IL-36R Antibodies | |
SG195072A1 (en) | Cd3-binding molecules capable of binding to human and non-human cd3 | |
MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
TN2014000258A1 (en) | Compositions and methods for antibodies targeting factor p | |
AU2016219704A1 (en) | Anti-Notch1 antibodies | |
MY162511A (en) | Engineered anti-tslp antibody | |
MX2013013832A (es) | Proteínas de unión receptoras fc. | |
EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
PH12015501687A1 (en) | Novel binding proteins from pcsk9 | |
MX337203B (es) | Novedosas moleculas inhbidoras de jnk. | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
AU2012323781A8 (en) | Antibodies to CD1d | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
TN2013000388A1 (en) | Anticoagulant antidotes | |
WO2012095432A3 (fr) | Agents de liaison à tlr3 | |
WO2014100117A3 (fr) | Procédés d'utilisation de la chromatographie échangeuse d'ions pour commander les taux de glycoformes à mannose élevé |